ONCOS-102 Shows Promise in Combination Mesothelioma Treatment
ONCOS-102, a promising immunotherapy vaccine, is moving closer to becoming a part of future first-line treatment for mesothelioma. Early clinical trial results announced this week show safety and efficacy when the vaccine is used in combination with standard-of-care chemotherapy for patients with inoperable pleural mesothelioma. Targovax, a Scandinavian pharmaceutical company developing the drug, is moving forward with another study combining ONCOS-102 with a checkpoint inhibitor drug such as Keytruda (pembrolizumab) or Opdivo (nivolumab), along with chemotherapy. “We have seen enough data at this point to be going full-steam ahead with larger randomized trials,” Dr. Magnus Jaderberg, chief medical officer at Targovax, told The Mesothelioma Center at Asbestos.com. “The data points to a real benefit with this emerging combination.” Find Clinical Trials for Mesothelioma Patients Get free help finding and enrolling in a mesothelioma clinical trial today! Find a Clinical Trial Survival Times Increase The drug combination including ONCOS-102 had a median progression-free survival of 8.4 months, compared to 6.8 months for the control group receiving only chemotherapy. Patients receiving the immunotherapy vaccine showed a 90% control rate, 7% better than the control group. The median progression-free survival was 4.5 months for the combination. Results are considered still emerging and are expected to change...
More News: Alimta | Asbestosis | Cancer | Cancer & Oncology | Cancer Vaccines | Chemotherapy | Clinical Trials | Environmental Health | Finland Health | France Health | Immunotherapy | Melanoma | Mesothelioma | Ovarian Cancer | Ovaries | PET Scan | Prostate Cancer | Skin Cancer | Spain Health | Study | Vaccines